NEWS RELEASE
Released: January 20, 2009
Department of Defense Ovarian Cancer Research Program (OCRP)
Funding for Fiscal Year 2009 (FY09)
The Fiscal Year 2009 (FY09) Defense Appropriations Act provides $20 million to the Department of Defense
Ovarian Cancer Research Program (OCRP) to eliminate ovarian cancer by supporting high impact, innovative
research. In striving to achieve this goal, the FY09 OCRP is supporting unique partnerships and fostering the next
generation of investigators in ovarian cancer. This program is administered by the US Army Medical Research and
Materiel Command (USAMRMC) through the Office of the Congressionally Directed Medical Research Programs (CDMRP).
The FY09 OCRP seeks proposals from all of areas of ovarian cancer research. However, proposals are encouraged that
specifically address critical needs of the ovarian cancer community in the following areas:
- Initiation and precursor lesion in ovarian cancer with emphasis on the role of the fallopian tube in disease
pathogenesis.
- Molecular understanding of disease heterogeneity.
- Validation of biomarkers for diagnosis, molecular imaging, and therapeutic response.
FY09 OCRP Program Announcements/Funding Opportunities for proposals in the following mechanisms are anticipated to
be posted and available on Grants.gov in January 2009.
| Award Mechanism |
Eligibility |
Key Mechanism Elements |
Funding |
| Idea Development Award |
Must be an independent investigator. |
- Supports high-impact, innovative research that will drive the field forward.
- Proposals in all areas of ovarian cancer-focused research are accepted.
- Proposals in the following three areas are encouraged:
- Initiation and precursor lesion in ovarian cancer with emphasis on the role of the fallopian tube in
disease pathogenesis.
- Molecular understanding of disease heterogeneity.
- Validation of biomarkers for diagnosis, molecular imaging, and therapeutic response.
- Preliminary data relevant to the proposed project are required; however, these data do not necessarily
need to come from the ovarian cancer research field.
- Clinical trials are allowed.
- Preproposal is required; proposal submission is by invitation only.
NEW FOR FY09:
- Optional nested Teal Predoctoral Scholar: Proposals having predoctoral candidates that
meet the criteria outlined in the Program Announcement/Funding Opportunity will qualify for a higher level of
funding.
|
- Maximum period of performance is 3 years.
- Maximum allowable direct costs for this mechanism are $375,000 (plus indirect costs).
- Maximum allowable direct costs with a qualified nested Teal Predoctoral Scholar are $475,000 (plus
indirect costs).
- Anticipate 14 awards.
|
| Collaborative Translational Research Award |
- Initiating PI: Must be an independent investigator.
- Partnering PIs: Must be independent investigators.
|
- Supports collaborations between clinicians and laboratory scientists that accelerate the movement of
promising ideas in ovarian cancer into clinical applications.
- Supports 3-4 independent investigators collaborating on a translational research effort
that must address one or more of the three Areas are Emphasis:
- Initiation and precursor lesion in ovarian cancer with emphasis on the role of the fallopian tube in
disease pathogenesis.
- Molecular understanding of disease heterogeneity.
- Validation of biomarkers for diagnosis, molecular imaging, and therapeutic response.
- Each of the 3-4 investigators will be a PI. A separate award will be made to each PI's
institution.
- At least one PI must be a clinician, and at least one PI must have experience either in ovarian cancer
research or ovarian cancer patient care.
- Must be multi-institutional and multi-disciplinary.
- Preliminary data relevant to the proposed project are required; however, these data do not necessarily
need to come from the ovarian cancer research field.
- Preproposal is required; proposal submission is by invitation only.
NEW FOR FY09
- Phase 0 and Phase I clinical trials are allowed.
|
- Maximum period of performance is 3 years.
- Maximum allowable direct costs for this mechanism are $1.125M for 3 PIs and 1.5M for 4 PIs (plus indirect
costs).
- Anticipate 1 award.
|
| Ovarian Cancer Academy |
- PI (Mentee): Must be in first faculty position.
- Academy Dean: Must be an established ovarian cancer researcher.
|
- Supports a virtual Academy by providing research funding and intensive, national networking, mentoring,
and a peer group for junior faculty with the goal of being successful, high profile ovarian cancer
researchers in the future.
- Designated Mentor who is an experienced ovarian cancer researcher with ovarian cancer
funding is required for Mentees.
- Required institutional match for mentor/mentee pairs.
- The Academy will be led by the "Academy Dean."
- Proposals in the following three areas are encouraged:
- Initiation and precursor lesion in ovarian cancer with emphasis on the role of the fallopian tube in
disease pathogenesis.
- Molecular understanding of disease heterogeneity.
- Validation of biomarkers for diagnosis, molecular imaging, and therapeutic response.
- Preliminary data relevant to the proposed project are required; however, these data do not necessarily
need to come from the ovarian cancer research field.
- Clinical trials are not allowed.
|
- Maximum period of performance for this mechanism is 5 years.
- PI (Mentee): Maximum allowable directs costs are $750,000 (plus indirect costs).
- Academy Dean: Maximum allowable direct costs are $625,000 (plus indirect costs).
- Anticipate 7 awards
|
All proposals must conform to the final Program Announcements/Funding Opportunities and application instructions
that will be available for electronic downloading from the Grants.gov website in late January 2009. Deadlines will
not be available until the Program Announcements are released. The application package containing the required
forms for each award mechanism will also be found on Grants.gov. A listing of all USAMRMC funding opportunities can
be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.
A pre-application is required and must be submitted through the CDMRP eReceipt website
(http://cdmrp.org) prior to application submission. Applications must be submitted
through the federal government's single-entry portal, Grants.gov. Requests for email notification of the Program
Announcements/Funding Opportunities release may be sent to Help@cdmrp.org. For
more information about the OCRP or other CDMRP-administered programs, please visit the CDMRP website
(https://cdmrp.health.mil).
Point of Contact:
